Work

CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma—Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.8037

Authors: Philip L. McCarthy, Sarah A. Holstein, Sin-Ho Jung, Miranda Cooper, Craig J Gibson, Edward Allen Stadtmauer, Benjamin Winograd, Paul G. Richardson

Institutions: Roswell Park Comprehensive Cancer Center, Duke University, Duke Medical Center, BresMed, Celgene (United States), Abramson Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891224192

Cites:

Cited by: 2

Related to: 10